John Kramer, PA-C
Articles
Concluding Thoughts on Biosimilars in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
Biosimilar Discussion With Patients and Biosimilar Resources
Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.
Implementing Biosimilars in Clinical Practice
Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.
Access to and Challenges to Biosimilar use in Clinical Practice
John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.
Comparison of AFFIRM (Reference Natalizumab) and Antelope (Biosimilar Natalizumab) Trials
Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.
Natalizumab Biosimilar in Development in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.
Cost Savings with Biosimilars and Use in Multiple Sclerosis
Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.
Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.
Approval Process for Biosimilars
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.
Comparison of Biosimilar Products and Reference Products
Clinical experts discuss differences and similarities between biosimilars and reference products.
